Commonly Reported Side Effects Based on community reports, side effects appear relatively uncommon and typically mild: Most Frequently Reported: Injection site reactions (redness, minor pain, itching) Mild nausea (particularly with oral administration) Temporary dizziness Headache Fatigue Less Commonly Reported: Skin flushing Changes in appetite Temporary mood changes Vivid dreams Theoretical Concerns Growth Factor Effects: BPC-157's upregulation of growth factors raises theoretical concerns for: Cancer promotion in those with existing malignancies Acceleration of undiagnosed tumors Effects on benign growths (polyps, fibroids) No evidence directly supports these concerns, but caution is warranted given the mechanisms involved
Specifically, the addition of cuprizone (bis-cyclohexanone oxalydihydrazone), to the diet process (66) produces a massive demyelination in different areas of the CNS and particularly in the corpus callosum (67-69)
& Hoffmann, A
Potential Interactions Between Semaglutide and Glutathione No direct pharmacokinetic interactions between semaglutide and glutathione have been documented in clinical trials
NHS access to Wegovy is restricted according to NICE TA875, which specifies that treatment must be initiated within specialist weight management services (tier 3 or 4) and is limited to specific patient groups meeting defined criteria
Cognitive impairment after long COVID-19: current evidence and perspectives
